NEW YORK -- The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Trials are under way for a new non-MRNA COVID vaccine from Novavax.Along the Gulf Coast, AMR Clinical in Daphne and Mobile ...

HOUSTON, Texas (KTRK) -- Pfizer and Moderna doses are making their way to cities across the country, but it's simply not enough to meet the need. "Right now, there's a huge demand for a limited supply ...

Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive licensing agreement with Pfizer, granting the pharmaceutical giant access to ...

CHICAGO, Oct 30 (Reuters) - Novavax Inc (NVAX.O), opens new tab on Friday outlined specific diversity targets for its large-scale COVID-19 vaccine study expected to begin in the United States and ...

(Reuters) - Novavax Inc has begun a large late-stage study of its experimental COVID-19 vaccine in the United States, the drug developer said on Monday, after delaying the trial twice due to issues in ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.